Krystal Biotech (KRYS) Stock Forecast, Price Target & Predictions
KRYS Stock Forecast
Krystal Biotech stock forecast is as follows: an average price target of $210.33 (represents a 34.57% upside from KRYS’s last price of $156.30) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
KRYS Price Target
The average price target for Krystal Biotech (KRYS) is $210.33 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $220.00 to $205.00. This represents a potential 34.57% upside from KRYS's last price of $156.30.
KRYS Analyst Ratings
According to 8 Wall Street analysts, Krystal Biotech's rating consensus is 'Buy'. The analyst rating breakdown for KRYS stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Krystal Biotech Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Dae Gon Ha | Stifel Nicolaus | $220.00 | $185.00 | 18.92% | 40.75% |
| Sep 02, 2024 | Alec Stranahan | Bank of America Securities | $205.00 | $195.12 | 5.06% | 31.16% |
| Aug 12, 2024 | Gavin Clark-Gartner | Evercore ISI | $206.00 | $182.17 | 13.08% | 31.80% |
| Apr 15, 2024 | Dae Gon Ha | Stifel Nicolaus | $204.00 | $169.75 | 20.18% | 30.52% |
| Nov 07, 2022 | Geulah Livshits | Chardan Capital | $133.00 | $78.05 | 70.40% | -14.91% |
| Aug 08, 2022 | Geulah Livshits | Chardan Capital | $130.00 | $82.40 | 57.77% | -16.83% |
The latest Krystal Biotech stock forecast, released on Sep 11, 2024 by Dae Gon Ha from Stifel Nicolaus, set a price target of $220.00, which represents a 18.92% increase from the stock price at the time of the forecast ($185.00), and a 40.75% increase from KRYS last price ($156.30).
Krystal Biotech Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $208.75 |
| Last Closing Price | $156.30 | $156.30 | $156.30 |
| Upside/Downside | -100.00% | -100.00% | 33.56% |
In the current month, the average price target of Krystal Biotech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Krystal Biotech's last price of $156.30. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 04, 2024 | Citigroup | Neutral | Neutral | Hold |
| Sep 11, 2024 | Wedbush | Underperform | Underperform | Hold |
| Sep 11, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 11, 2024 | National Securities Corporation | Buy | Buy | Hold |
| Aug 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 12, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Aug 05, 2024 | Citigroup | Buy | Neutral | Downgrade |
| Feb 27, 2024 | Citigroup | Buy | Buy | Hold |
| Feb 27, 2024 | Guggenheim | Buy | Buy | Hold |
| May 22, 2023 | Barclays | Buy | Buy | Hold |
| Feb 28, 2023 | Goldman Sachs | Buy | Upgrade |
Krystal Biotech's last stock rating was published by H.C. Wainwright on Dec 18, 2024. The company gave KRYS a "Buy" rating, the same as its previous rate.
Krystal Biotech Financial Forecast
Krystal Biotech Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.56M | - | - | - |
| Avg Forecast | $226.17M | $195.91M | $165.57M | $145.26M | $142.10M | $143.72M | $138.26M | $102.78M | $118.01M | $111.59M | $110.67M | $90.14M | $91.63M | $82.94M | $65.27M | $47.37M | $28.55M | $6.29M | $142.86K | $663.41K | $290.29K |
| High Forecast | $226.17M | $195.91M | $165.57M | $145.26M | $142.10M | $143.72M | $138.26M | $102.78M | $118.01M | $111.59M | $110.67M | $90.14M | $91.74M | $83.56M | $65.27M | $47.37M | $44.93M | $6.29M | $142.86K | $796.10K | $348.34K |
| Low Forecast | $226.17M | $195.91M | $165.57M | $145.26M | $142.10M | $143.72M | $138.26M | $102.78M | $118.01M | $111.59M | $110.67M | $90.14M | $91.51M | $82.33M | $65.27M | $47.37M | $12.82M | $6.29M | $142.86K | $530.73K | $232.23K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.36% | - | - | - |
Krystal Biotech's average Quarter revenue forecast for Dec 23 based on 6 analysts is $28.55M, with a low forecast of $12.82M, and a high forecast of $44.93M. KRYS's average Quarter revenue forecast represents a 233.70% increase compared to the company's last Quarter revenue of $8.56M (Sep 23).
Krystal Biotech EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.99M | $-23.12M | $-3.98M | $-2.13M |
| Avg Forecast | $196.91M | $170.56M | $144.15M | $126.47M | $123.72M | $125.13M | $120.37M | $89.48M | $102.75M | $97.16M | $96.35M | $78.48M | $79.78M | $72.21M | $56.83M | $41.24M | $24.86M | $5.48M | $124.38K | $-5.11M | $-3.18M |
| High Forecast | $196.91M | $170.56M | $144.15M | $126.47M | $123.72M | $125.13M | $120.37M | $89.48M | $102.75M | $97.16M | $96.35M | $78.48M | $79.87M | $72.75M | $56.83M | $41.24M | $39.12M | $5.48M | $124.38K | $-4.09M | $-2.54M |
| Low Forecast | $196.91M | $170.56M | $144.15M | $126.47M | $123.72M | $125.13M | $120.37M | $89.48M | $102.75M | $97.16M | $96.35M | $78.48M | $79.67M | $71.68M | $56.83M | $41.24M | $11.16M | $5.48M | $124.38K | $-6.14M | $-3.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.74% | -185.87% | 0.78% | 0.67% |
undefined analysts predict KRYS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Krystal Biotech's previous annual EBITDA (undefined) of $NaN.
Krystal Biotech Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $80.75M | $-41.77M | $-4.11M | $-2.15M |
| Avg Forecast | $83.28M | $67.03M | $50.60M | $50.04M | $39.49M | $41.99M | $40.19M | $25.25M | $39.09M | $37.10M | $36.63M | $32.50M | $36.17M | $29.71M | $21.91M | $7.96M | $-9.22M | $-35.92M | $-43.01M | $-4.61M | $-3.02M |
| High Forecast | $83.28M | $67.03M | $50.60M | $50.04M | $39.49M | $41.99M | $40.19M | $25.25M | $39.09M | $37.10M | $36.63M | $32.50M | $48.86M | $30.16M | $21.92M | $7.96M | $-354.56K | $-35.92M | $-43.01M | $-3.69M | $-2.42M |
| Low Forecast | $83.28M | $67.03M | $50.60M | $50.04M | $39.49M | $41.99M | $40.19M | $25.25M | $39.09M | $37.10M | $36.63M | $32.50M | $28.61M | $29.25M | $21.91M | $7.96M | $-16.84M | $-35.92M | $-43.01M | $-5.53M | $-3.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.25% | 0.97% | 0.89% | 0.71% |
Krystal Biotech's average Quarter net income forecast for Dec 23 is $-9.22M, with a range of $-16.84M to $-354.56K. KRYS's average Quarter net income forecast represents a -111.42% decrease compared to the company's last Quarter net income of $80.75M (Sep 23).
Krystal Biotech SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $23.70M | $24.04M | $1.53M | $757.00K |
| Avg Forecast | $268.73M | $232.77M | $196.73M | $172.60M | $168.84M | $170.77M | $164.28M | $122.12M | $140.22M | $132.59M | $131.50M | $107.10M | $108.87M | $98.55M | $77.56M | $56.28M | $33.92M | $7.48M | $169.74K | $775.15K | $339.18K |
| High Forecast | $268.73M | $232.77M | $196.73M | $172.60M | $168.84M | $170.77M | $164.28M | $122.12M | $140.22M | $132.59M | $131.50M | $107.10M | $109.01M | $99.28M | $77.56M | $56.28M | $53.38M | $7.48M | $169.74K | $930.18K | $407.01K |
| Low Forecast | $268.73M | $232.77M | $196.73M | $172.60M | $168.84M | $170.77M | $164.28M | $122.12M | $140.22M | $132.59M | $131.50M | $107.10M | $108.73M | $97.83M | $77.56M | $56.28M | $15.23M | $7.48M | $169.74K | $620.12K | $271.34K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.17% | 141.60% | 1.97% | 2.23% |
Krystal Biotech's average Quarter SG&A projection for Dec 23 is $33.92M, based on 6 Wall Street analysts, with a range of $15.23M to $53.38M. The forecast indicates a 43.16% rise compared to KRYS last annual SG&A of $23.70M (Sep 23).
Krystal Biotech EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.88 | $-1.62 | $-0.29 | $-0.21 |
| Avg Forecast | $2.79 | $2.24 | $1.69 | $1.67 | $1.32 | $1.40 | $1.34 | $0.84 | $1.31 | $1.24 | $1.23 | $1.09 | $1.21 | $0.99 | $0.73 | $0.27 | $-0.31 | $-1.20 | $-1.44 | $-0.33 | $-0.67 |
| High Forecast | $2.79 | $2.24 | $1.69 | $1.67 | $1.32 | $1.40 | $1.34 | $0.84 | $1.31 | $1.24 | $1.23 | $1.09 | $1.63 | $1.01 | $0.73 | $0.27 | $-0.01 | $-1.20 | $-1.44 | $-0.33 | $-0.54 |
| Low Forecast | $2.79 | $2.24 | $1.69 | $1.67 | $1.32 | $1.40 | $1.34 | $0.84 | $1.31 | $1.24 | $1.23 | $1.09 | $0.96 | $0.98 | $0.73 | $0.27 | $-0.56 | $-1.20 | $-1.44 | $-0.33 | $-0.81 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.40% | 1.13% | 0.88% | 0.31% |
According to 6 Wall Street analysts, Krystal Biotech's projected average Quarter EPS for Dec 23 is $-0.31, with a low estimate of $-0.56 and a high estimate of $-0.01. This represents a -110.70% decrease compared to KRYS previous annual EPS of $2.88 (Sep 23).